Technological Center “NovaMedica Innotech” started its activities in April 2017 in Moscow. It is a 100% subsidiary of the pharmaceutical company NovaMedica which was established by Rusnano, state investment corporation, and Domain Association (USA), venture capital company. The center was created to develop new drugs and pilot production of solid dosage forms in accordance with the GMP standards.
NovaMedica Innotech has a unique set of innovative technological platforms for the development and production of modern competitive and effective medicines. Specialists of the R&D Center of NovaMedica Innotech develop own original products and carry out a number of projects within contracts with Russian and foreign partners.
Due to the highly qualified staff, cooperation with leading global R&D centers and leaders in various segments of the pharmaceutical industry, NovaMedica Innotech is the center of competence transfer in the field of drug development in Russia in accordance with the best global practices of GLP, GMP.
![]() |
![]() |
![]() |
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
15 December 2022
4 Key Priorities for the European Medicines Agency in 2023
02 June 2023
CRISPR-based microbial gene therapy delivers promise
02 June 2023
FDA Releases Final Guidance on Adjusting for Covariates in Randomized Clinical Trials
01 June 2023
Small biotech turns CRISPR against bacteria, reducing E. coli in small early study
01 June 2023